Obesity & metabolic patent intelligence

US 9687461

Method for detecting risk factor for metabolic syndrome or hyperferritinemia

United States of America as represented by the Secretary of the Air Force · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9662306

Compositions and methods for diagnosis and treatment of metabolic syndrome

United States of America as represented by the Secretary of the Air Force · Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9649291

Treatment for obesity

Jazz Pharmaceuticals International III Limited · Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9603949

Oligonucleotide-based probes for detection of bacterial nucleases

INTEGRATED DNA TECHNOLOGIES, INC. · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9561206

Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome

United States of America as represented by the Secretary of the Air Force · Granted Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9549955

Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9545441

Treatment of diabetes

XBIOTECH INC. · Granted Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9517228

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

Jenrin Discovery, LLC · Granted Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9511103

AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9511038

Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

The Regents of the University of California · Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9463254

Molecular design toward dual-modality probes for radioisotope-based imaging (PET or SPECT) and MRI

The Board of Regents of the University of Texas System · Granted Tue Oct 11 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9433624

Methods and compositions for the treatment of metabolic disorders

BIOMARIN PHARMACEUTICAL INC. · Granted Tue Sep 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9393271

GHRH agonists for islet cell transplantation and function and the treatment of diabetes

THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Jul 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9226910

Treatment for obesity

Jazz Pharmaceuticals International III Limited · Granted Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9221800

Isoxazole treatments for diabetes

The Board of Regents of the University of Texas System · Granted Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9220735

Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders

AKER BIOMARINE ANTARCTIC AS · Granted Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9198901

Tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist and pharmaceutical compositions and uses thereof

VTV THERAPEUTICS LLC · Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9186421

Establishment of rhesus monkey model of autoimmunity type 1 diabetes

WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Tue Nov 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9163258

Method for the treatment of obesity

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9149448

Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

The Regents of the University of California · Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9138479

Formulations for the treatment of diabetes

XERIS PHARMACEUTICALS, INC. · Granted Tue Sep 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9133127

Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

Jenrin Discovery, LLC · Granted Tue Sep 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9120813

Oxadiazoanthracene compounds for the treatment of diabetes

VTV THERAPEUTICS LLC · Granted Tue Sep 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9095550

Methods for treating diabetic wounds

CALREGEN INC. · Granted Tue Aug 04 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9089531

GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

The Regents of the University of California · Granted Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9067962

Methods of treating diabetes

LEXICON PHARMACEUTICALS, INC. · Granted Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9056847

Activity based probes (ABPs) interacting with glycosidases

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM · Granted Tue Jun 16 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9029413

Treatment of viral infections by modulation of host cell metabolic pathways

THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue May 12 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9006201

Prophylactic or therapeutic agent for diabetes

Takeda Pharmaceutical Company Limited · Granted Tue Apr 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8987198

Compositions and methods for treating obesity and diabetes

United States Department of Agriculture · Granted Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8961982

Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer

The Regents of the University of California · Granted Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8957070

Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity

Takeda Pharmaceutical Company Limited · Granted Tue Feb 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8889133

Methods of treating diabetes with Dll4 antagonists

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8865914

Fluorescent probes for detection of copper

The Regents of the University of California · Granted Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8853215

Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes

Takeda Pharmaceutical Company Limited · Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8853160

GLP-1, exendin-4, peptide analogs and uses thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8853252

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

Jenrin Discovery, LLC · Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8828971

Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders

GALECTIN THERAPEUTICS, INC. · Granted Tue Sep 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8741589

Monitoring two dimensions of diabetes pathogenesis

The Regents of the University of California · Granted Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8729115

Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases

CARDIOLYNX AG · Granted Tue May 20 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8722716

Isoxazole treatments for diabetes

The Board of Regents of the University of Texas System · Granted Tue May 13 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8697628

Methods of using AMPD2 inhibitors for the treatment of fatty liver, obesity and diabetes

The Regents of the University of Colorado, a Body Corporate · Granted Tue Apr 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8697138

Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders

Aker Biomarine AS · Granted Tue Apr 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8680131

Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

Jenrin Discovery, LLC · Granted Tue Mar 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8653027

Method of treatment of type-1 diabetes with humanin analogues

The Regents of the University of California · Granted Tue Feb 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8648072

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

Jenrin Discovery, LLC · Granted Tue Feb 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8580768

Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes

Jenrin Discovery, LLC · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8580919

Polymer conjugates of GLP-1

Nektar Therapeutics · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)